Table 1A.
Characteristics of patients whose thymus and TECs were used for experiments.
| Patient ID | Degree of thymic hyperplasia (1) | Interval onset - thymectomy (months) | MGFA score at thymectomy (2) | Corticoid treatment (3) | Cholinesterase inhibitors | Anti-AChR titer (nmol/L) | PCR on thymic extracts | PCR on TECs | In situ hybridization |
|---|---|---|---|---|---|---|---|---|---|
| MG1 | Low | 13 | III b | No | Yes | 3.45 | X | ||
| MG2 | Low | 7 | II a | No | Yes | 2118.7 | X | X | |
| MG3 | Low | 7 | I a | No | NS | 83.7 | X | ||
| MG4 | Low | 24 | IV a | No | Yes | 11.1 | X | ||
| MG5 | Low | 6 | II a | No | Yes | >100 | X | ||
| MG6 | Low | 6 | NS | No | Yes | 17.3 | X | ||
| MG7 | High | 2 | IV a | No | NS | >100 | X | X | |
| MG8 | High | 14 | I | No | NS | 3180.2 | X | ||
| MG9 | High | 3 | II a | No | Yes | 3.21 | X | ||
| MG10 | High | 4 | II a | No | Yes | 60.38 | X | ||
| MG11 | High | 36 | III a | No | Yes | 9.7 | X | ||
| MG12 | High | 2 | III a | No | Yes | 264 | X | ||
| MG13 | No hyperplasia | 6 | IV b | Yes | Yes | 30.02 | X | ||
| MG14 | No hyperplasia | 18 | III a | Yes | Yes | 0.5 | X | ||
| MG15 | No hyperplasia | 30 | II b | Yes | Yes | 4.33 | X | ||
| MG16 | No hyperplasia | 6 | III a | Yes | Yes | 3.46 | X | ||
| MG17 | Low | 18 | II b | Yes | Yes | NS | X | ||
| MG18 | No hyperplasia | 18 | V | Yes | Yes | 6.9 | X | ||
| MG19 | Low | 24 | NS | Yes | Yes | 4.4 | X | ||
| MG20 | NS | 9 | III a | Yes | Yes | 9.6 | X | ||
| MG21 | No hyperplasia | 60 | NS | Yes | Yes | 21.4 | X | ||
| MG22 | Low | 10 | II a | Yes | Yes | 26.1 | X | ||
| MG23 | No hyperplasia | 12 | NS | Yes | Yes | 6.6 | X | ||
| MG24 | No hyperplasia | 30 | II a | Yes | Yes | NS | X | ||
| MG25 | Low | 3 | III a | No | Yes | 14 | X | ||
| MG26 | High | 18 | IV a | No | Yes | >100 | X | ||
| MG27 | Low | 34 | IV b | Yes | Yes | 206.57 | X | ||
| MG28 | Low | 3 | II a | No | Yes | >100 | X | ||
| MG29 | Low | 48 | III b | No | Yes | 0.38 | X | ||
| MG30 | High | 9 | NS | No | Yes | NS | X | ||
| MG31 | Low | 18 | IV a | No | Yes | 670 | X | ||
| MG32 | Low | 33 | NS | Yes | Yes | >100 | X | ||
| MG33 | Low | 26 | II a | No | Yes | 87.6 | X | ||
| MG34 | Low | 84 | II b | No | Yes | 35.3 | X | ||
| MG35 | NS | 24 | NS | No | Yes | NS | X | ||
| MG36 | Low | NS | NS | No | Yes | NS | X | ||
| MG37 | Low | 6 | II a | No | Yes | 1.1 | X | ||
| MG38 | High | 4 | II a | No | Yes | 60.38 | X | ||
| MG39 | High | 2 | IV a | NS | NS | >100 | X | ||
| MG40 | High | 3 | II a | No | Yes | 3.21 | X |
Patients are females (37), aged from 15 to 44, and males (3) aged from 20 to 35. (1) Degree of thymic hyperplasia: low hyperplasia (with 2 or fewer GCs per section) or high hyperplasia (with 3 or more GCs per section). (2) Clinical classification according to the Myasthenia Gravis Foundation of America (MGFA). (3) Patients with corticoid treatment were only used for RT-PCR in Figure 1A. NS, not specified.